Www.cebm.net Evidence-Based Medicine Thread Course Dr Carl Heneghan Director CEBM Clinical Reader, University of Oxford.

Slides:

Advertisements

Similar presentations

Cardiovascular Side Effects of HIV Treatment

Advertisements

Independent Prescribing and the Clinical Research Nurse Dr Kathryn Jones Deputy Director of Nursing For the Research Nurse Professional Development Meeting:

Measures of effect: relative risks, odds ratios, risk difference and number needed to treat Giovanni Tripepi, Kitty J. Jager 1, Friedo W. Dekker 1,2, Christoph.

Major Cancer Milestones

Progress Against Prostate Cancer. 1970–1979 Progress Against Prostate Cancer 1970–1979 Early 1970s: Radioactive ''seeds'' proven effective for prostate.

Progress Against Lung Cancer. 1970–1979 Progress Against Lung Cancer 1970–1979 Mid-1970s: Chemotherapy combinations prove effective in small cell lung.

Progress Against Stomach Cancer. 1980–1989 Progress Against Stomach Cancer 1980– : Combination chemotherapy improves outcomes for advanced stomach.

Progress Against Testicular Cancer. 1970–1979 Progress Against Testicular Cancer 1970– : Two new drugs produce first complete remissions in advanced.

Progress Against Head and Neck Cancer. 1970–1979.

Progress Against Melanoma. 1970–1979 Progress Against Melanoma 1970– : Hereditary syndrome linked to increased melanoma risk.

Progress Against Leukemia. 1970–1979 Progress Against Leukemia 1970– : FDA approves doxorubicin.

Progress Against Kidney Cancer. 1970–1979 Progress Against Kidney Cancer 1970– : Removing just part of the cancerous kidney is proven safe and.

Progress Against Pancreatic Cancer. 1970–1979 Progress Against Pancreatic Cancer 1970– s: Tobacco use found to cause pancreatic cancer.

A rational Medicines Policy for Europe Danielle Bardelay Medicines in Europe Forum HAI Seminar - The Hague 18 November2004.

The golden standard or fools gold Selective data, impact on safety Clinical trials on trial HAI Europe Open Seminar 2008 Neues Stadthaus, Berlin, 21 November.

THE COMMONWEALTH FUND Figure 1. Health Insurance Coverage and Uninsured Trends Data: Analysis of the U.S. Census Bureau, Current Population Survey Annual.

Heart Disease and Stroke Statistics 2011 Update 1.

Interrupted Time Series: What, Why and How Karen Smith An Example From Suicide Research.

Evidence Based Health Care Course Paris, 2010 Appraising diagnostic studies Dr Matthew Thompson Senior Clinical Scientist.

1 Cell-Free Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death Natason et al., JAMA, Prepublished online April 28, 2008 at.

The Seroquel documents Seroquel (quetiapine): AstraZeneca’s atypical antipsychotic Many issues raised in documents released through litigation process.

Cardiac Resynchronization Heart Failure Study Cardiac Resynchronization Heart Failure Study Presented at American College of Cardiology Scientific Sessions.

Statin Landmark Trials Across the Spectrum of Risk: Secondary CV Prevention.

Name ____________________ Date ___________ Period ____.

1-day workshop on Evidence-Based Practice November 26 th 2010 Dr Carl Heneghan Clinical Reader, University of Oxford Director CEBM.

3-Day workshop on Evidence-Based Practice March 26 th 2012 Dr Carl Heneghan Director CEBM Clinical Reader, University of Oxford.

Prof. Carl Heneghan Director CEBM University of Oxford

Looking for lower value and overuse Professor Carl Heneghan Director CEBM University of Oxford.

Evidence-Based Practice April 8 th 2013 Dr Carl Heneghan Clinical Reader, University of Oxford Director CEBM.

Therapy-Related Cardiac Toxicity in Cancer Patients JEAN-BERNARD DURAND, M.D., FCCP, FACC ASSOCIATE PROFESSOR OF MEDICINE MEDICAL DIRECTOR CARDIOMYOPATHY.

Critical Reading VTS 22/04/09. “How to Read a Paper”. Series of articles by Trisha Greenhalgh - published in the BMJ - also available as a book from BMJ.

TXA in trauma patients: who should we treat and when?

Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:

Virginia Falcón Advisor: Prof. Prashant Yadav. US $2.5 billions in annual sales lawsuits May 1999: FDA approves Vioxx March 2000: study reveals.

FDA Reprimands Merck for the Release: “…you fail to disclose that your explanation is hypothetical, has not been demonstrated by substantial evidence,

Evidence-based Medicine Journal Club Khalid Bin Abdulrahman Director of Medical Education Center King Saud University.

VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.

Treating to New Targets Study TNT Trial Presented at The American College of Cardiology Scientific Sessions 2005 Presented by Dr. John C. LaRosa.

An Update on NSAID Labeling and Data Review DSaRM Advisory Committee February 10, 2006 Sharon Hertz, M.D. Deputy Director Division of Anesthesia, Analgesia,

EVIDENCE BASED MEDICINE Effectiveness of therapy Ross Lawrenson.

Diabetes Mellitus 101 for Medical Professionals An Aggressive Pathophysiologic Approach to Cardiometabolic Therapy for Type 2 Diabetes: Stan Schwartz MD,FACP.

CAST: Cardiac Arrhythmia Suppression Trial Purpose To determine whether therapy with class Ic antiarrhythmics to suppress asymptomatic or mildly symptomatic.

Cardiovascular Risk and NSAIDs Arthritis Advisory Committee Meeting November 29, 2006 Sharon Hertz, M.D. Deputy Director Division of Analgesia, Anesthesia,

Cardiovascular Risk and NSAIDs Arthritis Advisory Committee Meeting April 12, 2007 Sharon Hertz, M.D. Deputy Director Division of Analgesia, Anesthesia,

Evaluating the Medical Evidence A TOOLKIT FOR THE INTERPRETING THE EFFECTIVENESS OF INTERVENTIONS Niteesh Choudhy, M.D., Ph.D.

Introduction to Evidence-Based Medicine Dr Hayfaa A.A Wahbi Assistant Professor, Chair of Evidence Based Medicine and Knowledge translation.

What about VIOXX?. Adenomatous Polyp Prevention on Vioxx (APPROVe) Vioxx (rofecoxib) versus Placebo Basic Clinical Trial Objective: Assess whether Vioxx.

Candesartan in Heart Failure Presented at European Society of Cardiology 2003 CHARM Trial.

European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003 EUROPA.

Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.

Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.

Drug Regulation in Controversy: Vioxx November 10, 2004 Sandra L. Kweder, M.D. Deputy Director, Office of New Drugs Center for Drug Evaluation and Research.

1 Evidence based health SCREENING Dr.Hathaitip Tumviriyakul Diploma Family medicine,Hatyai Hospital Msc. Epidemiology LSHTM,UK.

Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:

The AURORA Trial Source: Holdaas H, Holme I, Schmieder RE, et al. Rosuvastatin in diabetic hemodialysis patient. J Am Soc Nephrol. 2011;22(7):1335–1341.

CHEST 2013; 144(3): R3 김유진 / Prof. 장나은. Introduction 2  Cardiovascular diseases  common, serious comorbid conditions in patients with COPD cardiac.

CRITICAL APARAISAL OF A PAPER ON THERAPY

VIOXX WITHDRAWAL: Learning valuable lessons from rofecoxib

1. Evidence based management:

REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Louise Bowman on behalf of the HPS.

EVIDENCE BASED MEDICINE

First time a CETP inhibitor shows reduction of serious CV events

Pharmacovigilance (PV)

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

Relative risk of major events with atenolol vs placebo

Trial Selection Process

Baseline Characteristics of Cardiovascular Risk Factors and Selected Dietary Variables in a Cohort of 22,881 Men and 35,091 Women to Quintile of Fish Intakes.

Illustration of a trial design to help evaluate the clinical accuracy of a test of ischaemia. Illustration of a trial design to help evaluate the clinical.

Introduction to Evidence Based Medicine

Number of patients treated at clinics that followed up fewer than 10 patients (2013–2016) or 20 patients (2012) and proportion of patients followed up.

Presentation transcript:

Evidence-Based Medicine Thread Course Dr Carl Heneghan Director CEBM Clinical Reader, University of Oxford

Why do we need EBM? A more detailed account of the MRC patulin trial is available in: Chalmers I, Clarke M. The 1944 patulin trial: the first properly controlled multicentre trial conducted under the aegis of the British Medical Research Council. International Journal of Epidemiology 2004;32:

ACTIVE INGREDIENTS WITHDRAWN THALIDOMIDE (1961)Congenital limb defects BENOXAPROFEN (1982)Hepatotoxicity PHENFORMIN (1982)Lactic acidosis FENFLURAMINE (1997)Heart-valve abnormalities ASTEMIZOLE (1999)Many drug interactions PHENYLPROPANOLAMINE(2000) Hemorrhagic stroke KAVA KAVALiver abnormalities CERIVASTATIN (2001)Rhabdomyolysis CISAPRIDE (2000)Cardiac arrhythmias ROFECOXIB (2004)Cardiovascular events VALDECOXIB (2005)CVD events, skin reactions COMFREY, SENECIONephrotoxicity TEGASEROD (2007)Cardiovascular events CLOBUTINOL (2007) Cardiac arrhythmia Co-PROXAMOL (2007)Respiratory arrest XIMELEGTRAN (2008)Liver toxicity SIBUTRAMINE (2010)Cardiovascular events

Why do we need RANDOMIZED CONTROLLED TRIALS ? In the early 1980s newly introduced antiarrhythmics were found to be highly successful at suppressing arrhythmias. The CAST trial revealed Excess mortality of 56/1000. By the time the results of this trial were published, at least 100,000 such patients had been taking these drugs.

ACTIVE INGREDIENTS WITHDRAWN THALIDOMIDE (1961)Congenital limb defects BENOXAPROFEN (1982)Hepatotoxicity PHENFORMIN (1982)Lactic acidosis FENFLURAMINE (1997)Heart-valve abnormalities ASTEMIZOLE (1999)Many drug interactions PHENYLPROPANOLAMINE(2000) Hemorrhagic stroke KAVA KAVALiver abnormalities CERIVASTATIN (2001)Rhabdomyolysis CISAPRIDE (2000)Cardiac arrhythmias ROFECOXIB (2004)Cardiovascular events VALDECOXIB (2005)CVD events, skin reactions COMFREY, SENECIONephrotoxicity TEGASEROD (2007)Cardiovascular events CLOBUTINOL (2007) Cardiac arrhythmia Co-PROXAMOL (2007)Respiratory arrest XIMELEGTRAN (2008)Liver toxicity SIBUTRAMINE (2010)Cardiovascular events

1000

Informed FDA in 2001 there was no increase in risk of death while they knew internally it was 3 times that of placebo Spending $100 million dollars per year in direct to advertising consumers 2003 sales $2.5 billion per year

Merck, Rofecoxib & Alzheimers Internal company data April 2001 from 2 Vioxx trials Information submitted to the FDA in July 2001 used on ‐ treatment analysis that minimized the appearance of any mortality risk Psaty et al. JAMA 2008;299:1813 ‐ 7

On treatment analysis April 2001, Company's internal intention-to-treat analyses of pooled data from these 2 trials identified a significant increase in total mortality Overall mortality of 34 deaths among 1069 rofecoxib patients and 12 deaths among 1078 placebo patients HR, 2.99 (95% CI, ).

The 5 steps of EBM 1.Formulate an answerable question 2.Track down the best evidence 3.Critically appraise the evidence for validity, clinical relevance and applicability 4.Individualize, based clinical expertise and patient concerns 5.Evaluate your own performance